<?xml version="1.0" encoding="UTF-8"?>
<p id="Par117">The anti-tumor effects of SGN-35 are evaluated only in patients with measurable lesions according to the Revised Response Criteria for Malignant Lymphoma [
 <xref ref-type="bibr" rid="CR13">13</xref>] based on the results of cervical, thoracic, abdominal, and pelvic computed tomography (CT) and positron emission tomography (PET), which were performed at the points established in the study protocol. At each point, the treatment response is assessed as CR, PR, SD, or PD. Lesions meeting the following criteria are regarded as measurable:
 <list list-type="bullet">
  <list-item>
   <p id="Par118">Nodular masses of lymph nodes or extranodular organs evaluated as lymphoma on CT</p>
  </list-item>
  <list-item>
   <p id="Par119">The lesion can be clearly measured in two intersecting directions on cross sections of CT.</p>
  </list-item>
  <list-item>
   <p id="Par120">The maximum diameter exceeds 1.5Â cm on cross sections of CT.</p>
  </list-item>
  <list-item>
   <p id="Par121">Positive findings on FDG-PET.</p>
  </list-item>
 </list>
</p>
